Crestor 20 mg 28 tablets

Crestor 20 mg 28 tablets

Composition:

Each p/o tablet contains:

Rosuvastatin – 20 mg.

Description:

Rosuvastatin is a synthetic lipid-lowering agent from the statin group, an inhibitor of HMG-CoA reductase. Inhibition of HMG-CoA reductase activity leads to a series of successive reactions, resulting in a decrease in intracellular cholesterol content and a compensatory increase in LDL receptor activity, which accelerates the catabolism of LDL cholesterol (LDL-C).

Indications:

-Treatment of hypercholesterolemia in adults with primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia) or mixed hypercholesterolemia (type IIb) as an adjunct to diet when diet and other non-drug treatments (exercise, weight loss) are inadequate.

-Homozygous familial hypercholesterolemia as an adjunct to diet and other cholesterol-lowering therapy, or when such therapy is inappropriate for the patient.

-Slowing the progression of atherosclerosis as an adjunct to diet in patients requiring therapy to reduce total cholesterol and LDL-C levels.

-Primary prevention of major cardiovascular complications (stroke, heart attack) in adult patients without clinical signs of coronary artery disease but at increased risk of its development.

How to Use:

Take orally, swallowing the tablet whole with water. The drug can be taken at any time of the day, regardless of food intake.

-Before starting therapy, patients should follow a standard hypocholesterolemic diet and continue it during treatment.

-The dose should be selected individually based on therapeutic goals. The recommended starting dose is 5 or 10 mg once daily. If necessary, the dose may be increased after 4 weeks.

-Due to the potential for side effects at a 40 mg dose, such a dose should only be used in patients with severe hypercholesterolemia and high cardiovascular risk who have not achieved desired outcomes with a 20 mg dose. Careful monitoring is recommended for patients on the 40 mg dose.

-No dose adjustment is needed for elderly patients or those with mild to moderate renal insufficiency. For moderate renal impairment, an initial dose of 5 mg is recommended.

-Increased systemic concentrations of rosuvastatin have been observed in individuals of Japanese and Chinese descent. For these populations, the recommended initial dose is 5 mg when prescribing 10 or 20 mg doses.

Contraindications:

-Hypersensitivity to rosuvastatin or any component of the drug.

-Lactose intolerance, lactase deficiency, or glucose-galactose malabsorption.

-Age under 18 years.

-Active liver disease.

-Severe renal dysfunction.

-Myopathy.

-Concurrent use of cyclosporine.

-Pregnancy and lactation.

Precautions:

Use with caution in:

-Renal failure, hypothyroidism, personal or family history of hereditary muscle diseases, or a history of muscle toxicity with other HMG-CoA reductase inhibitors.

-Chronic alcoholism.

-Patients over 65 years old.

-History of liver disease, sepsis, arterial hypotension, major surgical interventions, trauma, severe metabolic, endocrine, or electrolyte disorders.

-Uncontrolled epilepsy.

-People of Asian origin (Chinese, Japanese).

-When taking rosuvastatin at a 40 mg dose, kidney function indicators should be monitored. Liver function tests should be conducted before starting therapy and three months after therapy initiation. Treatment should be stopped or the dose reduced if serum transaminase levels exceed three times the upper limit of normal.

Side Effects:

The drug is generally well-tolerated. Adverse events are usually mild and transient:

-Common: Headache, myalgia, asthenia, constipation, dizziness, nausea, abdominal pain, diabetes mellitus.

-Less common: Itching, rash, hives, myopathy, hypersensitivity reactions, pancreatitis, jaundice, hepatitis, arthralgia, memory loss.

Storage:

Store at a temperature not exceeding 30°C, in a place protected from moisture and out of reach of children.

Packaging:

The package contains 28 tablets.